The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using high ...

Enniskillen author and charity trustee Clare Donohoe recently addressed the Interstitial Lung Disease (ILD) Interdisciplinary ...

Diffuse (interstitial) lung disease includes a wide variety of relatively uncommon conditions presenting with characteristic clusters of clinical features and marked by an immune response.

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

In propensity score-matched cohorts of 121,046 hospitalized patients, those with RA and T2D had an ILD prevalence of 2.25%, ...

Interstitial lung disease (ILD), a condition characterized by inflammation and fibrosis, is a major cause of severe respiratory illness ... In a head-to-head study, FAPI PET/CT was found to be ...

Interstitial Lung Disease (ILD) is a chronic condition marked by lung inflammation and scarring that makes breathing difficult. Early diagnosis is vital for effective management. Contributing ...

Enniskillen author and charity trustee Clare Donohoe recently addressed the Interstitial Lung Disease (ILD) Interdisciplinary Network conference ...

IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function. It is a specific type of interstitial lung disease, which includes various ...

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

Today, the American Lung Association Research Institute announced a $22 million research investment in the past year, making ...